Abstract:Hydroxamic acid group is one of the characteristic pharmacophores of histone deacetylase (HDAC) inhibitors. But here, we discovered a series of hydroxamic acid-based microtubule destabilizing agents (MDAs), which were derived from shortening the length of the linker in HDAC6 inhibitor SKLB-23bb. Interestingly, the low nanomolar antiproliferative activity of these MDAs depended on the presence of hydroxamic acid groups, but their inhibitory effects on HDAC were lost. Among them, 12b showed favorable metabolism stability, high bioavailability, and potent antitumor activity in multidrug-resistant cell lines and A2780/T xenograft model. More importantly, in the patient-derived xenograft models of triple-negative breast cancer and osimertinib-resistant non-small-cell lung cancer, both 20 mg/kg oral and 10 mg/kg intravenous administration of 12b could induce more than 70% tumor inhibition without obvious toxicity. Overall, we discovered that 12b, as a novel MDA based on hydroxamic acid, could serve as a potential MDA for further investigation.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01451.Inhibitory activity of compounds 7b and SKLB-23bb on HDAC1 and HDAC6 (Table S1); antiproliferative activity of 7b and SKLB-23bb against various tumor cell lines (Table S2); structure and antiproliferative activity of compounds 7a–e (Table S3); metabolic stability of 7b in mouse and human liver microsomes (Table S4); inhibitory activity of 12b on HDAC2-5 and HDAC7-11 (Table S5); effects of 1 μM 12b on the activity of 144 cancer-related kinases (Table S6); binding free energy for α and β chain of tubulin in 12b/tubulin and 12c/tubulin complex systems and decomposition of electrostatic interaction, van der Waals interaction, solvation free energies, and entropy (Tables S7 and S8); 3-week toxicity study of 12b on hematologic and biochemistry parameters of female BALB/c mice (Tables S9 and S10); immunofluorescence staining of the microtubule network in A2780S cells treated with 7b (Figure S1); immunofluorescence staining of the microtubule network in A2780S cells treated with 8b to 14b (Figure S2); antitumor effects of 11b, 12b, and 14b on C26 homograft mouse model (Figure S3); effect of 12b on Ac-H3 and Ac-α-tubulin protein levels of A2780S cells after treatment for 12 h (Figure S4); validation of protein–ligand docking model (protein: 4O2B; ligand: colchicine) (Figure S5); binding modes of the compounds (12a, 12c–e) and colchicine binding site (PDB code: 4O2B) (Figure S6); kinetic binding 100 ns MD simulation on 12b and 12c with tubulin–colchicine complex 4O2B (Figure S7); RMSD values of heavy atoms of backbone for protein and heavy atoms of inhibitor along 100 ns MD simulation for inhibitor/tubulin systems (Figure S8); snapshots of the 12b/tubulin and 12c/tubulin along the dynamic simulation times for 20, 40, 60, 80, and 100 ns as well as the aligned conformations (Figures S9 and S10); effects of compound 12b on the body weight of BALB/c mice during dosing phase (Figure S11); effects of compound 12b on the organ tissues of BALB/c mice at the end of 3-week dosing phase (Figure S12); HPLC, NMR, HRMS, and IR spectra of final compound 12b; except for the compound synthesis method, and all of the other experimental methods involved in this article and the results of 12b and 12c molecular dynamics simulation and binding free energy calculation (PDF)Molecular formula strings and antiproliferation activity of compounds (CSV)PDB code 4O2B was used for modeling docking of 12a–e in the colchicine site (ZIP)This article has not yet been cited by other publications.

Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design and Synthesis of Cantharidin Derivative DCZ5418 As a TRIP13 Inhibitor with Anti-Multiple Myeloma Activity in Vitro and in Vivo

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Icaritin promotes tumor T‐cell infiltration and induces antitumor immunity in mice

Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-B]pyridazine Derivatives As Mtor Inhibitors

Design, Synthesis and Biological Evaluation of Novel Diarylpyridine Derivatives As Tubulin Polymerisation Inhibitors

Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation

Antitumor Mechanism and Therapeutic Potential of Cordycepin Derivatives

A Novel Pi3k Inhibitor Identified by A High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma

Antitumor Effects of Icaritin and the Molecular Mechanisms.

Design, Synthesis and in Vitro Biological Evaluation of 2-Aminopyridine Derivatives As Novel PI3Kδ Inhibitors for Hematological Cancer.

Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways

Novel Podophyllotoxin Derivatives as Potential Tubulin Inhibitors: Design, Synthesis and Anti-proliferative Activity Evaluation.

Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2- d ]pyrimidine derivatives as Mnk1/2 inhibitors

Design and synthesis of 1 H -benzo[ d ]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma

Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway